NAMSW · NewAmsterdam Pharma Company N.V. Warrant
View on chartInsiders & Stakes
| Michael H. Davidson Chief Executive Officer | ▲ Buy | Open Market | 792,923 Shares held | 9/14/2026 | View profile |
| Johannes Jacob Pieter Kastelein Chief Scientific Officer | ▼ Sell | Open Market | 69,302 Shares held | 9/30/2026 | View profile |
Transaction History
| Johannes Jacob Pieter Kastelein | ▲ Buy | Option Exercise | 50,246 | — | 9/30/2026 |
| Johannes Jacob Pieter Kastelein | ▼ Sell | Open Market | 50,246 | $1.3M | 9/30/2026 |
| Michael H. Davidson | ▲ Buy | Open Market | 10,000 | $227K | 9/14/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
NewAmsterdam Pharma's SPINOZA Trial May Shift Alzheimer Strategy
NewAmsterdam Pharma is conducting a genotype‑targeted SPINOZA trial that could alter its long‑term Alzheimer approach. The study focuses on personalized treatment based on genetic markers. Results may influence the company's future research priorities.
NewAmsterdam Pharma's SPINOZA Trial May Shift Alzheimer Strategy. NewAmsterdam Pharma is conducting a genotype‑targeted SPINOZA trial that could alter its long‑term Alzheimer approach. The study focuses on personalized treatment based on genetic markers. Results may influence the company's future research priorities.